Medicines Transparency Alliance16/12/2015 1 MeTA Uganda: Promotion Nazeem Mohamed MeTA Council Co-Chair.

Slides:



Advertisements
Similar presentations
Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Advertisements

A study of advertisements in five African countries
Regulation of Pharmaceutical Promotion: assessment, analysis & advocacy Lilia Ziganshina 20 May 2009 WHA.
Armand Racine Consultant Chemicals Branch
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
Promoting patient-centred healthcare around the world Advancing the fight against counterfeit medicines Ms. Regina Kamoga IAPO Board Member, Country Manager,
Group 3 Irrational use of Medicine and medical technology.
Vision: A strong and capable civil society, cooperating and responsive to Cambodia’s development challenges Host of the 2nd Global Assembly for CSO Development.
MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.
First Evaluation of Good Governance for Medicines Programme Brief Summary of Findings.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
The Role of Regulation in the development of the postal sector in Uganda A presentation to the conference on Leveraging of ICTs in the transformation of.
Access to Medicine Index 3 rd International Conference for Improving the Use of Medicines Poster 599 Tuesday 15 th November 2011.
Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.
ADB Support of Public Procurement Reform Presented By: Amr J. Qari, Procurement Specialist Seventh Regional Public Procurement Forum, May , 2011.
FORMATION OF THE GHANA MeTA CIVIL SOCIETY NETWORK : AN OVERVIEW 1 Allotey. C; 2 Ahiabu. R.K.A; 3 Ntoso. R.Y; 4 Azumah. S.K; 5 Andoh.I 1,5. Health Access.
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
Medicines Transparency Alliance05/09/2015 Medicine Promotion Robert Louie P. So, MD Program Manager DOH - National Center for Pharmaceutical Access and.
Reflections and Digital Storytelling Amy Pittenger.
Medicines Transparency Alliance13/09/ MeTA Uganda Country Overview Public Sector Private Sector Civil Society.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
Medicines Transparency Alliance18/09/ MeTA Kyrgyzstan Country Overview Public Sector Civil Society.
INTRODUCTION TO RA.
GRASSROOTS DEMOCRACY ORDINANCE PPWG HANOI, MAY 2007.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Data Disclosure: An Ongoing Progress Towards Transparency Abeer Rabayah B.Sc Pharmacy -MBA /Marketing MeTA National Coordinator.
Page 1 Regulation: Catalyst for better governance and enhanced integrity in water utilities? Experiences from GIZ Water Programmes Regulation: Catalyst.
Promoting adaptation and climate resilient growth through devolved district climate finance Phase 1: June 2013 – September 2014.
Medicines Transparency Alliance10/10/2015 Updates on Quality Presentations et al. John Allotey Manager, Business Developments LaGray Chemical Company Limited.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
Medicines Transparency Alliance14/10/ Medicines promotion: innovative tools to promote rational use Carole Piriou Project officer Rational use of.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Medicines Transparency Alliance27/10/ MeTA Ghana Augustina Koduah (Mrs) Country Coordinator.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from.
Codes of Conduct The International Pharmaceutical Regulatory & Compliance Congress and Best Practice Forum 6 June 2007 Heather Simmonds Director Prescription.
ABHI Presentation to RCS October MD Regulatory Reform AGENDA EU Council Conclusions June 2011 What Needs Improving Industry Recommendation for New.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
META PHILIPPINES WORKPLAN : EARLY ACCOMPLISHMENTS IN THE PILOT PHASE.
1 CTO CONFERENCE ON “IMPLEMENTING WSIS ACTION PLAN” NAIROBI, KENYA, MARCH 2004 UGANDA’S REGULATORY INNOVATIONS By Patrick F. Masambu Executive Director,
Socio-political context Heavy political influence over media outlets that results with lack of freedom of speech, limited independence, biased media, censorship.
Medicines Transparency Alliance Presented by Gilles Forte Department of Essential Medicines and Health Products, WHO On behalf of WHO and HAI Technical.
Medicines Transparency Alliance16/12/2015 Pricing: Observations Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O.
Medicines Transparency Alliance18/12/ Country overview MeTA Kyrgyzstan Mariam Djankorozova MeTA Country coordinator.
Medicines Transparency Alliance31/01/ MeTA Uganda Jacqueline Idusso Secretariat Coordinator.
PUBLIC INSTITUTIONS INVOLVED IN ACCESS AND BENEFIT SHARING OF GENETIC RESOURCES IN DEVELOPING COUNTRIES: THE CASE OF UGANDA BY DAVID R. MUTEKANGA (PhD)
1 Corporate Governance Market and Regulations. 2 Framework of Corporate Governance.
Trade & Access to Medicines in India Centre for Trade & Development
Implementation of Insurance Core Principles and FSAP Evaluations The Portuguese FSAP experience Gabriel Bernardino Instituto de Seguros de Portugal.
Pharmaceutical Working Group Working Group on Pharmaceuticals Key Points for Advocacy and Action.
IMPACT - Regional Meeting on Combating Counterfeit Medical Products 9-10 November 2009, Kempton Park South Africa WHO Survey on situation of counterfeit.
AFR Observatory on monitoring and evaluating procurement reform programs Working for a world free of poverty.
Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines.
Competition Advocacy: Need and Importance Udai S Mehta Director, CUTS International.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
The IFPMA Code and how to set up a national self-regulation system Presentation to China/EU Pharmaceutical Industry Forum 17 May 2017, Shanghai, China.
Improving the Garment Sector in Lao PDR:
A Presentation Organized By
WHO Medicines Work in Countries: The Kenya Example
A Case for Employment Quotas for Persons with Disabilities in the Public Service Hassan Waddimba, East Africa Center for Disability Law and Policy (EA-Cdlp)
Fight Against Falsified medicines
La voix des Consommateurs à travers le monde
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
SECURITY AND RISK MANAGEMENT CONSULTANT
Presentation transcript:

Medicines Transparency Alliance16/12/ MeTA Uganda: Promotion Nazeem Mohamed MeTA Council Co-Chair

Medicines Transparency Alliance16/12/20152 Situational Analysis Laws and guidelines on promotion of medicines exist National Drug Authority responsible for enforcement Promotion generally carried out by pharmaceutical companies and herbalists Market mostly generic hence promotion limited Promotional materials vetted and licensed for use for one year

Medicines Transparency Alliance Issues/Challenges Monitoring and enforcement of guidelines is weak Disparity in regulation of herbals and conventional medicine Self-regulatory mechanisms undeveloped due to few players Consumer knowledge and awareness minimum 16/12/20153

Medicines Transparency Alliance Lessons Learned MeTA pilot tool tested: – No role played by CSO in regulation – Public unaware that promotion of medicines is regulated – Enforcement not clear – Traditional herbalists not regulated – “WHO Ethical Criteria” unknown 16/12/20154

Medicines Transparency Alliance Recommendations Harmonisation of regulation on promotion in the East Africa region Increase capacity of the regulatory authorities (NDA, professional councils, UNBS) to enforce the law/guidelines Prioritise dissemination of patient information on medicines Empower CSOs to monitor drug promotion 16/12/20155